Product Images Bortezomib

This text appears to be a table displaying the percentage of patients at different time intervals, along with the number of patients at risk. However, the table is not very legible or interpretable without additional context. It is not possible to further interpret the text provided.*

Not available. The text provided is incomplete and does not give enough context to generate a description.*

This appears to be a table displaying the number of patients remaining after a certain timepoint for two treatments - Bortezomib and Dexamethasone. There is also a p-value from a log-rank test. However, there is not enough context to determine what condition or disease is being treated or how the treatments were administered.*

This text seems to indicate the comparison of two chemotherapy regimens (R-CHOP and VcR-CAP) to treat a certain illness in terms of their effectiveness over a period of 48 months. The number of patients receiving each regimen and their progress is also shown. However, without additional context, it is difficult to provide a more detailed description.*

This is a single-dose vial medicine with NDC code 50742-484-01. It contains Bortezomib and is intended for intravenous or subcutaneous use. The contents of the vial include 3.5 mg bortezomib and 35 mg manitol, with the usual dose provided in the accompanying package insert. The medicine should be stored at 25°C with excursions permitted from 15°C to 30°C, and should be protected from light. The manufacturer is Ingenus Pharmaceuticals, LLC based in Orlando, Florida, and the product was made in China. The text also warns that the medicine is a cytotoxic agent and any unused portion should be discarded.*

This appears to be a label for a medication called "Bortezomib", with dosage information and instructions for use. It is also indicated as a cytotoxic agent, which likely means it is used to treat cancer. The label warns of its potential dangers and advises to only use it as instructed.*